Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are widely used in Kenya to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been growing steadily in recent years, driven by various factors.
Customer preferences: Kenyan customers prefer affordable and effective bronchodilator drugs. They are willing to switch to generic brands that offer the same benefits as branded drugs at a lower cost. However, they also value quality and safety, and therefore rely on prescriptions from qualified healthcare professionals.
Trends in the market: The Bronchodilator Drugs market in Kenya has been witnessing a shift towards combination therapy, where two or more bronchodilator drugs are used together to achieve better outcomes. This trend is driven by the need for more effective treatment options for severe respiratory diseases. The market is also witnessing an increase in the use of long-acting bronchodilators, which provide sustained relief from symptoms.
Local special circumstances: Kenya has a high prevalence of respiratory diseases, especially among children and young adults. This is attributed to various factors such as pollution, poor indoor air quality, and exposure to tobacco smoke. As a result, there is a high demand for bronchodilator drugs in the country.
Underlying macroeconomic factors: The Kenyan economy has been growing steadily in recent years, with a focus on healthcare infrastructure development. This has led to an increase in the availability of healthcare facilities and qualified healthcare professionals, which has in turn led to an increase in the diagnosis and treatment of respiratory diseases. Additionally, the government has introduced policies to encourage local production of pharmaceuticals, which has led to an increase in the availability of affordable generic drugs. In conclusion, the Bronchodilator Drugs market in Kenya is witnessing a shift towards combination therapy and long-acting bronchodilators. The market is driven by the high prevalence of respiratory diseases, increased availability of healthcare facilities and qualified healthcare professionals, and government policies to encourage local production of pharmaceuticals. Kenyan customers prefer affordable and effective bronchodilator drugs and rely on prescriptions from qualified healthcare professionals.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
